US EditionEyestem releases positive results from phase 1 trial in patients with geographic atrophy
Summary by ophthalmologytimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
All
Left
Center
Right
Eyestem Research's phase 1/2a trial results find significant vision improvements in patients treated with Eyecyte-RPE for GA
The first 6 patients in the study had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within 4 to 6 months post transplantation.
Successful trial results announced for potential rare eye disease treatment - Pharmafile
Eyestem Research, an Indian biotech company, announced successful results from its phase 1 trial of Eyecyte-RPE, a potential therapy for a rare form of dry age-related macular degeneration (AMD), geographic atrophy (GA). GA is an advanced form of AMD, which affects a small number of AMD patients. The phase 1 trial found advancement in visual […] The post Successful trial results announced for potential rare eye disease treatment appeared first o…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
